Logotipo de Valence
populares
Iniciar sesión
Loading data for AVR — first visit, this takes a few seconds.

Añadir a la lista de seguimiento

Anteris Technologies Glob...

NasdaqGM: AVR · Precio en tiempo real · USD
9.42
+0.02 (0.21%)
Al cierre: Aug 18, 2026, 3:59 PM

Anteris Technologies Global Corp. (AVR) Stock Price, Analysis & Data

0.21%
Precio de compran/a
Capitalización de mercado918.06M
Ingresos (TTM)2.24M
Beneficio neto (TTM)-103.56M
Betan/a
EPS (TTM)-1.95
Ratio PER (TTM)n/a
Adelante PE-10.64
P/B (TTM)3.65
P/S (TTM)408.99
Earnings DateNov 12, 2026
Precio de ventan/a
Volumen487,098
Volumen medio (20D)1,272,524
Abierto9.27
Anterior Cerrar9.40
Rango del día9.22 - 9.60
Rango de 52 semanas3.30 - 11.05
analistan/a
Precio objetivon/a
Dividendosn/a
Fecha ex dividendon/a

Acerca de AVR

Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of severe aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also develops ADAPT anti-calcification tissue, an anti-calcification prepa...

[Leer más]
Industria Medical Instruments & Supplies
Sector Healthcare
IPO Fecha Dec 13, 2024
Empleados 174
Bolsa de Valores NasdaqGM
Símbolo bursátil AVR
Sitio web https://anteristech.com
Perfil completo de la empresa

Desempeño financiero

En 2023, los ingresos de Anteris Global fueron 2.73M, una disminución de -14.56% en comparación con 3.2M del año anterior. Las ganancias fueron -46.02M, un aumento de 50.58%.

Estados financieros

Sorpresa de resultados

Anteris Global ha publicado sus resultados trimestrales en Aug 11, 2026:
  • Ingresos de n/a falla las estimaciones por $0, con NaN% Crecimiento interanual.
  • EPS de -0.3 falla las estimaciones por -0.09, con 50.82% Crecimiento interanual.

    • Próxima publicación de resultados

    Está previsto que Anteris Technologies Global Corp. publique sus resultados el Nov 12, 2026, durante el horario de mercado.
    Los analistas proyectan ingresos de ... Actualizar
    news image

    1 semana hace · Proactive

    Anteris Technologies advances PARADIGM Trial in June quarter as US patient recruitment gets underway

    Anteris Technologies Pty Ltd (ASX:AVR, NASDAQ:AVR) made progress on its pivotal PARADIGM Trial during the June quarter, enrolling and treating its first US patients after securing Medicare reimburseme...

    news image

    2 meses hace · Proactive

    France clearance marks key milestone for Anteris' pivotal PARADIGM Trial

    Anteris Technologies Pty Ltd (ASX:AVR, NASDAQ:AVR) has secured full regulatory clearance from France's National Agency for Medicines and Health Products Safety (ANSM) for its global pivotal PARADIGM T...

    news image

    3 meses hace · Simply Wall St.

    Here's Why We're Not Too Worried About Anteris Technologies Global's (ASX:AVR) Cash Burn Situation

    We can readily understand why investors are attracted to unprofitable companies. For example, although...

    news image

    3 meses hace · Proactive

    Anteris adds Susan Knight, Stephen Denaro to board as company advances heart valve strategy

    Anteris Technologies Pty Ltd (ASX:AVR, NASDAQ:AVR) has strengthened its board with the appointments of experienced healthcare and finance executive Susan Knight and company veteran Stephen Denaro as d...

    news image

    3 meses hace · Proactive

    Anteris advances PARADIGM trial as Q1 cash burn reflects commercialisation push

    Anteris Technologies Pty Ltd (ASX:AVR, NASDAQ:AVR) has reported strong operational progress for the March 2026 quarter as the company advanced recruitment for its global PARADIGM pivotal trial and str...

    Página 1 de 2